Justin Zelen

Director and Senior Biotechnology Analyst at BTIG

Justin Zelin is a Director and Senior Biotechnology Analyst at BTIG, specializing in research on cell therapy, targeted oncology, immunology, and auto-immune disease therapeutics. He has provided coverage for companies including Viking Therapeutics, 89bio, Syndax Pharmaceuticals, Kura Oncology, Poseida Therapeutics, and ProKidney, and has published detailed investment recommendations for these firms, with his stock picks tracked by platforms like MarketBeat. Zelin began his equity research career after roles in academic and industry labs at organizations such as Agenus, Harvard University, and Brigham and Women’s Hospital, subsequently holding research analyst and associate positions at B. Riley Securities, Canaccord Genuity, and SVB Leerink before joining BTIG in January 2021. He holds both a master’s degree in biotechnology and a bachelor’s degree in biology from Harvard University, and leverages his formal scientific training and teaching experience at Harvard in his analytical approach.